Bayer’s Twin Tracks: A Pharma Win in the Lab as a Legal Storm Rages in Court
05.06.2026 - 20:44:29 | boerse-global.de
The Bayer share finds itself caught between two opposing forces. In the laboratory, the drug pipeline is delivering meaningful milestones—most recently a Priority Review designation from the US Food and Drug Administration for the experimental stroke drug Asundexian. In the courtroom, however, over 100,000 glyphosate-related lawsuits continue to cast a long shadow, and chief executive Bill Anderson has just escalated the conflict by threatening to halt all US production of the weedkiller.
The contrasting narratives are hard to reconcile. Asundexian, an FXIa inhibitor designed to prevent ischemic strokes without disrupting normal blood clotting, has the potential to become a first-in-class therapy for patients at high risk of recurrence. The FDA’s decision to grant Priority Review in May 2026 follows the publication of the pivotal phase III OCEANIC-STROKE trial in the New England Journal of Medicine—a clear signal of scientific credibility that bolsters the drug’s prospects with regulators and prescribing physicians alike.
Yet the market has barely acknowledged the news. At €36.10, the stock gained roughly 2 percent on the day—hardly the sort of breakout that a major regulatory win typically triggers. The shares remain almost 28 percent below their February high of €49.93, hovering just above the 200-day moving average of €35.80. The relative strength index sits at 43.5, a neutral reading that suggests investors are unwilling to commit either way.
That ambivalence is rooted in the legal morass. Anderson’s warning of a US production halt for glyphosate is as stark as it is risky: if implemented, it would ripple through American agriculture and underscore just how deeply the Monsanto legacy dominates Bayer’s present. The company has proposed a $7.25 billion global settlement, but some plaintiffs have rejected the deal, and a group of plaintiff attorneys is trying to move cases from Missouri to a California federal court where the presiding judge is considered hostile to Bayer. The management is fighting the venue shift while simultaneously lobbying for a political fix.
Should investors sell immediately? Or is it worth buying Bayer?
All of this comes against a backdrop of otherwise solid operational performance. First-quarter 2026 earnings per share beat expectations, the Crop Science division benefited from lucrative licensing deals, and Consumer Health posted growth. The free cash flow, however, is being gutted by settlement payouts—cash that could otherwise fund R&D or reinforce the pharma pipeline. Union Investment, a major shareholder, recently vented its frustration: the company needs margins, not visions. Profits, not promises.
Anderson has publicly ruled out a spin-off of the agricultural unit, insisting that the legal knot must be untangled within the existing corporate structure. Yet the clock is ticking. Before the end of June, the US Supreme Court is expected to issue a decision on a glyphosate-related appeal that could either open the door to a comprehensive legal resolution or leave Bayer exposed to a flood of new claims. A favorable ruling would give the company breathing room; an unfavorable one would turn Anderson’s production threat from a negotiating tactic into a real prospect.
Bayer’s pipeline, meanwhile, is broader than just Asundexian. The company describes 2026 as a year of multiple milestones spanning precision medicine, cardiovascular disease, oncology, cell and gene therapy, and molecular imaging. It already secured three new product approvals, two additional indications, and six positive phase III readouts in 2025. In May, it acquired Perfuse Therapeutics, a US biopharma firm focusing on ischemia-related eye diseases. The goal is mid-single-digit revenue growth from 2027 and an operating margin of roughly 30 percent by 2030.
Bayer at a turning point? This analysis reveals what investors need to know now.
But none of that long-term ambition will matter if the legal overhang persists. The market capitalisation of €33.5 billion reflects a deep discount—one that will only narrow when the courtroom doors finally close. For now, Bayer is running two races in parallel, and the finish line for one remains far more uncertain than the other.
Ad
Bayer Stock: New Analysis - 5 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
